What would you offer as systemic therapy to an elderly woman (age >75 years) with HR negative, HER2 positive, lymph node negative breast cancer whose tumor is 2 cm or less?

The risks and benefits of adjuvant chemotherapy and anti-HER2 therapy need to be weighed. Based on lack of evidence for anti-HER2 therapy use alone in the adjuvant setting, we recommend a regimen of chemotherapy with anti-HER2 therapy - either weekly paclitaxel / trastuzumab (Tolaney, 2017) or docet...